Charlotte Parker, Author at Oral Cancer News

Maura L. Gillison, M.D., Ph.D., Receives AACR’s Richard Hinda Rosenthal Memorial Award for her HPV research

CHICAGO — The American Association for Cancer Research awards Maura L. Gillison, M.D., Ph.D., with the 36th Annual AACR Richard and Hinda Rosenthal Memorial Award during the AACR Annual Meeting 2012. Gillison is receiving this award in recognition of her significant contributions to the understanding of the role of human papillomavirus (HPV) in head and neck cancers. “It is an honor to be the recipient of this award,” said Gillison. “Our team strives to generate data that will improve the lives of individuals affected by head and neck cancers, and this is a wonderful validation that we are on the right track.” This award is designed to provide incentive to young investigators early in their careers. It was established in 1977 by the AACR and the Rosenthal Family Foundation to recognize research that has made, or promises to make, a notable contribution to improved clinical care in the field of cancer. Gillison is a professor of medicine, epidemiology and otolaryngology and the Jeg Coughlin Chair of Cancer Research at Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute in Columbus, Ohio. She is also adjunct faculty at The Johns Hopkins University School of Medicine, in Baltimore, Md. Her seminal research on the role of HPV in head and neck cancers revolutionized the specialty. Her research has demonstrated that HPV infection causes a distinct molecular, clinical and pathological subset of head and neck squamous cell carcinomas. In a landmark case-control study, Gillison [...]

Charlotte Parker2012-07-26T06:42:52-07:00July, 2012|Oral Cancer News|

Best. Obit. Ever.

Source: News.Health.com This funny, surprising obituary was written by Val Patterson before he died of throat cancer earlier this month. I was Born in Salt Lake City, March 27th 1953. I died of Throat Cancer on July 10th 2012. I went to six different grade schools, then to Churchill, Skyline and the U of U. I loved school, Salt Lake City, the mountains, Utah. I was a true Scientist. Electronics, chemistry, physics, auto mechanic, wood worker, artist, inventor, business man, ribald comedian, husband, brother, son, cat lover, cynic. I had a lot of fun. It was an honor for me to be friends with some truly great people. I thank you. I’ve had great joy living and playing with my dog, my cats and my parrot. But, the one special thing that made my spirit whole, is my long love and friendship with my remarkable wife, my beloved Mary Jane. I loved her more than I have words to express. Every moment spent with my Mary Jane was time spent wisely. Over time, I became one with her, inseparable, happy, fulfilled. I enjoyed one good life. Traveled to every place on earth that I ever wanted to go. Had every job that I wanted to have. Learned all that I wanted to learn. Fixed everything I wanted to fix. Eaten everything I wanted to eat. My life motto was: “Anything for a Laugh”. Other mottos were “If you can break it, I can fix it”, “Don’t apply for a job, [...]

Charlotte Parker2012-07-19T09:14:20-07:00July, 2012|Oral Cancer News|

Gardasil vaccine to be free for boys for protection against human papilloma virus

Source: Herald Sun IN a world first, Australian schoolboys will receive the Gardasil vaccine free from next year. Federal Health Minister Tanya Plibersek's announcement yesterday comes five years after it was first funded for girls. She said about 870,000 boys would receive Gardasil over the next four years under the national immunisation program, costing about $21 million. The vaccine, which protects against four strains of the human papilloma virus, will be funded for 12 and 13-year-old boys, but Year 9 students will also be included in a two-year catch-up program. HPV causes cervical cancer in women, as well as a range of other cancers affecting both sexes, including tumours of the head and neck. Ms Plibersek made the announcement at Brisbane's Diamantina Institute, where the vaccine was developed. She said the decision continued Australia's reputation as being a world pioneer in immunisation. "We were one of the first countries to introduce polio and measles vaccinations," the Minister said. "We're the first country to provide free HPV vaccinations for girls, and from next year we will be the first country to provide free HPV vaccinations for boys." Scientist Ian Frazer, who developed Gardasil, hailed the "important public health measure". "The papillomavirus is responsible for some of the cancers inside the mouth and throat along with cancers of the genital tract," Prof Frazer said from overseas. "This is a very safe and effective vaccine." Cancer Council Australia CEO Ian Olver said funding Gardasil for girls was already having positive impacts, decreasing the [...]

Charlotte Parker2012-07-12T08:55:51-07:00July, 2012|Oral Cancer News|

HPV vaccine reduces infection, even in unvaccinated

Source: Therapeutics Daily The HPV vaccine not only has resulted in a decrease in human papillomavirus infection in immunized teens but also in teens who were not immunized. The study is believed to be the first to show a substantial decrease in HPV infection in a community setting as well as herd protection – a decrease in infection rates among unimmunized individuals that occurs when a critical mass of people in a community is immunized against a contagious disease. The Cincinnati Children's Hospital Medical Center study will be published online July 9 in the eFirst pages of Pediatrics. "Infection with the types of HPV targeted by the vaccine decreased in vaccinated young women by 69 percent," says Jessica Kahn, MD, MPH, a physician in the division of Adolescent Medicine at Cincinnati Children's and lead author of the study. "Two of these HPV types, HPV-16 and HPV-18, cause about 70 percent of cervical cancer. Thus, the results are promising in that they suggest that vaccine introduction could substantially reduce rates of cervical cancer in this community in the future." The first HPV vaccine was licensed for use in the United States in June 2006. The U.S. Advisory Committee on Immunization Practices has recommended vaccination of girls and women between the ages of 11 and 26 to reduce rates of HPV infection, which ultimately can lead to cervical cancer. In 2006 and 2007, Dr. Kahn and colleagues at Cincinnati Children's recruited 368 young women between the ages of 13 and 16 from [...]

Charlotte Parker2012-07-10T09:33:35-07:00July, 2012|Oral Cancer News|

A New Treatment’s Tantalizing Promise Brings Heartbreaking Ups and Downs

Source: The New York Times Beth McDaniel’s oncologist, a bear of a man, hugged her and twirled her around. “Holy cow, Beth!” Dr. John J. Gohmann exclaimed. For the first time since a rare cancer appeared eight years before, her lymph nodes had shrunk to a normal size, her skin was no longer bright red and inflamed, and the itchiness that plagued her had subsided. Mrs. McDaniel, the 69-year-old wife of a retired corporate executive, had gambled on the ultimate in personalized medicine, an approach known as whole genome sequencing, and it seemed to be paying off. Scientists had compared the entire genetic sequences of the tumor cells invading her body with those in her healthy cells, searching for mutated tumor genes that could be thwarted by drugs approved for other cancers or even other diseases. That had led them to give her an expensive drug approved just a month earlier for melanoma patients. It had never been given to anyone with a blood cell cancer like hers. In theory, the drug should have killed her. Instead, it seemed to have halted or even reversed her cancer. But would it last? And what would it mean if it did not? In the end, Mrs. McDaniel’s journey to the edge of genetics research turned out to be a decidedly mixed experience. It was hard — much harder than anyone in her family had imagined — to get the sequencing and analysis done. It was breathtaking to see the results, which indicated [...]

Charlotte Parker2012-07-09T09:31:57-07:00July, 2012|Oral Cancer News|

Viral Marketing: What’s Stopping Men From Getting the HPV Vaccine

Source: GOOD Mobile By: Jake Blumgart on July 6, 2012 at 3:00AM PDT In early 2011, my doctor informed me that a vaccine to protect against the human papillomavirus—HPV—was now available for men. I was relieved, then frustrated—my doctor didn’t actually offer the principal vaccine, Gardasil, to her male patients. After a couple days of hunting around town, I finally found the vaccine at the Mazzoni Center, a LGBT health clinic in downtown Philly. I received all three shots, and joined the less than 1 percent of American men who are vaccinated against the most dangerous strains of the virus. While I was exceedingly grateful to the Mazzoni Center inoculating me, I knew of only one other male friend who’d received his shots. So since I got my shots, I’ve made a point of discussing my experience with any friend, acquaintance, or bemused bystander who will listen. And I’ve learned two things about young, straight men and HPV: We all know it exists, and not much else. When I posted about my vaccinations on Facebook and Twitter, the response was largely positive—but the dozen or so likes and comments mainly came from my female friends. When I brought up the issue with a few straight guys, they seemed confused about my decision to air the information in public. Embarrassed, I let the conversation drop. But a couple weeks later, I received a Facebook message from an acquaintance in another city, freaking out about his own HPV scare, and asking me whether [...]

Charlotte Parker2012-07-09T09:04:05-07:00July, 2012|OCF In The News, Oral Cancer News|

Test for KRAS mutations clarifies who will benefit from EGFR treatments

Medscape Oncology Written by, Zosia Chustecka (Barcelona, Spain) — A simpler, cheaper, more accurate test forKRAS mutations has been developed by a group of Italian researchers. Routine testing for KRAS mutations in the treatment of colorectal cancer is now recommended by many expert bodies. Testing identifies patients who carry this mutation and are unlikely to respond to treatment with the anti–epidermal growth factor receptor (EGFR) monoclonal antibodies cetuximab (Erbitux, Bristol-Myers Squibb, Lillly) and panitumumab (Vectibix, Amgen). Targeted therapies are indicated only for use in patients with KRAS wild-type disease. Details on the new test were presented in a poster exhibited here at the 14th World Congress on Gastrointestinal Cancer, which was organized in partnership with the European Society for Medical Oncology. "This new test is cheaper, quicker, and more sensitive, so the genotyping of patient[s] is more accurate," senior author Christiana Lo Nigro, PhD, from the Laboratory for Cancer Genetics and Translational Oncology at the S. Croce General Hospital, in Cuneo, Italy, toldMedscape Medical News. Currently, the gold standard for KRAS mutation testing is Sanger sequencing of polymerase chain reaction (PCR) products. "Although this detects and identifies all mutations in an amplified sequence, it is time-consuming, cost-ineffective, and has a maximum sensitivity of around 15 to 20%," Dr. Lo Nigro stated. Another method — high-throughput pyrosequencing (PS) — is faster but still takes about a day. "It too is cost-ineffective," she said, because the equipment is expensive and is available in only a few centers. In addition, although PS has a detection limit of around 5%, about 5% [...]

Charlotte Parker2012-07-06T16:39:32-07:00July, 2012|Oral Cancer News|

Perspectives on Coping Among Patients With Head and Neck Cancer Receiving Radiation

Source: MedScape News Today Abstract and Introduction Abstract Purpose/Objectives: To describe coping among patients with laryngeal and oropharyngeal cancer during definitive radiation with or without chemotherapy. Research Approach: Qualitative content analysis conducted within a larger study. Setting: Two radiation oncology outpatient clinics in Baltimore, MD. Participants: 21 patients with oropharyngeal or laryngeal cancer. Methodologic Approach: Interviews with open-ended questions were conducted during treatment. Questions covered topics such as coping during treatment, treatment-related issues, and resources. Main Research Variables: Coping, treatment, and coping resources. Findings: Patients' self-assessments suggested they were coping or that coping was rough or upsetting. Issues that required coping varied over four time points. Physical side effects were problematic during and one month after treatment completion. Patients used coping to manage the uncertainties of physical and psychological aspects of their experience. Family and friend support was a common coping strategy used by patients, with the intensity of side effects corresponding with the support provided across time points. Conclusions: Findings confirm previous research, but also provide new information about ways in which patients with head and neck cancer cope with their illness experience. Emergent themes provide insight into patients' feelings, issues, and assistance received with coping. Interpretation: Patients with head and neck cancer need education on the amount and severity of side effects and should be appraised of potential difficulties with scheduling, driving, and other logistic issues. Patients also should be informed of helpful types of support and coping strategies. Additional research is needed to expand the findings related [...]

Charlotte Parker2012-06-27T10:08:59-07:00June, 2012|Oral Cancer News|

Darwin’s Principles Say Cancer Will Always Evolve to Resist Treatment

Source: ScienceDaily.com According to researchers at Moffitt Cancer Center, cancer is subject to the evolutionary processes laid out by Charles Darwin in his concept of natural selection. Natural selection was the process identified by Darwin by which nature selects certain physical attributes, or phenotypes, to pass on to offspring to better "fit" the organism to the environment. As applied to cancer, natural selection, a key principle of modern biology, suggests that malignancies in distinct "microhabitats" promote the evolution of resistance to therapies. However, these same evolutionary principles of natural selection can be applied to successfully manage cancer, say Moffitt researchers who published an opinion piece in a recent issue of Nature Reviews Cancer. "Understanding cancer as a disease starts with identifying crucial environmental forces and corresponding adaptive cellular strategies," said Robert A. Gatenby, M.D., chair of the Department of Diagnostic Imaging. "Cancer is driven by environmental selection forces that interact with individual cellular adaptive strategies." Cancer cell development, like any natural selection (or Darwinian) process, is governed by environmental selection forces and cellular adaptive strategies, the authors wrote. Investigating cancer and its proliferation through genetic changes and ignoring the adaptive landscape is most likely futile. Under "selective pressure" of chemotherapy, in this case the "adaptive landscape," resistant populations of cancer cells invariably evolve. The authors say that tumors can be thought of as "continents" populated by multiple cellular species that adapt to regional variations in environmental selection forces. Their strategy in offering this metaphor, they wrote, is to "integrate microenvironmental [...]

Charlotte Parker2012-06-22T12:53:19-07:00June, 2012|Oral Cancer News|

More On Why The Adverse Event Reports On Gardasil Don’t Point To A Problem

Source: Forbes.com Readers are still commenting on my post on why the adverse event reports on Gardasil seem to indicate the vaccine is safe. One particularly persuasive line of comment comes from reader Stephanie Rehak, who does some reporting for me. Basically, she points out, many of these reports are third-hand and for problems that a vaccine would be unlikely to cause. Rehak writes: Have you read through the (currently) 107 reports of death on VAERS tied to Gardasil? It’s well worth the read. The first page has mostly cases of death with other underlying factors that contributed to the patient’s death (congenital heart disease, seizure disorders, DVT in patients taking Yaz BCP). The further in you get the crazier it becomes. There are several fourth and fifth hand reports such as VAERS ID 344385 “Information has been received from an office manager that the physician heard from the physician”s colleague that a 16 year old female colleague”s patient was given an unspecified dose of GARDASIL (Lot not reported) on a Friday and on Monday the patient passed away (specific dates were unknown).” There are at least a dozen regarding cases the reporter read about on the internet, heard about on the radio or saw on TV, like 383175 “Information has been received from a consumer via an internet newspaper concerning a patient who on an unspecified date was vaccinated with a dose of GARDASIL… It was also reported that polysorbato 80 or tween 80 that is a chemical that causes [...]

Charlotte Parker2012-06-21T09:33:11-07:00June, 2012|Oral Cancer News|

Oral Cancer News
Compiled by The Oral Cancer Foundation

About Charlotte Parker